Fuzzy Fractal Analysis of Molecular Imaging Data

2008 ◽  
Vol 96 (8) ◽  
pp. 1332-1347 ◽  
Author(s):  
T.D. Pham
Keyword(s):  
Molecular Imaging ◽  
Fractal Analysis ◽  
Imaging Data

scholarly journals Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer’s disease

2015 ◽  
Vol 112 (31) ◽  
pp. 9734-9739 ◽  
Author(s):  
Xueli Zhang ◽  
Yanli Tian ◽  
Can Zhang ◽  
Xiaoyu Tian ◽  
Alana W. Ross ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Imaging ◽  
Amyloid Beta ◽  
Near Infrared ◽  
Imaging Data ◽  
Curcumin Analog ◽  
Near Infrared Fluorescence ◽  
Brain Extraction ◽  
Monitoring Therapy

Near-infrared fluorescence (NIRF) molecular imaging has been widely applied to monitoring therapy of cancer and other diseases in preclinical studies; however, this technology has not been applied successfully to monitoring therapy for Alzheimer’s disease (AD). Although several NIRF probes for detecting amyloid beta (Aβ) species of AD have been reported, none of these probes has been used to monitor changes of Aβs during therapy. In this article, we demonstrated that CRANAD-3, a curcumin analog, is capable of detecting both soluble and insoluble Aβ species. In vivo imaging showed that the NIRF signal of CRANAD-3 from 4-mo-old transgenic AD (APP/PS1) mice was 2.29-fold higher than that from age-matched wild-type mice, indicating that CRANAD-3 is capable of detecting early molecular pathology. To verify the feasibility of CRANAD-3 for monitoring therapy, we first used the fast Aβ-lowering drug LY2811376, a well-characterized beta-amyloid cleaving enzyme-1 inhibitor, to treat APP/PS1 mice. Imaging data suggested that CRANAD-3 could monitor the decrease in Aβs after drug treatment. To validate the imaging capacity of CRANAD-3 further, we used it to monitor the therapeutic effect of CRANAD-17, a curcumin analog for inhibition of Aβ cross-linking. The imaging data indicated that the fluorescence signal in the CRANAD-17–treated group was significantly lower than that in the control group, and the result correlated with ELISA analysis of brain extraction and Aβ plaque counting. It was the first time, to our knowledge, that NIRF was used to monitor AD therapy, and we believe that our imaging technology has the potential to have a high impact on AD drug development.

PET Brain Imaging Methodologies

2017 ◽  
Author(s):  
Ansel T. Hillmer ◽  
Kelly P. Cosgrove ◽  
Richard E. Carson
Keyword(s):  
Molecular Imaging ◽  
Brain Imaging ◽  
Volume Of Distribution ◽  
Group Differences ◽  
Binding Potential ◽  
Imaging Data ◽  
Imaging Studies ◽  
Standard Data ◽  
Positron Emission ◽  
Methodological Considerations

While quantitative and pharmacologically specific aspects distinguish molecular imaging, they also impose the need for considerable expertise to design, conduct, and analyze molecular imaging studies. Positron emission tomography (PET) brain imaging provides a powerful noninvasive tool for quantitative and pharmacologically specific clinical research. This chapter describes basic methodological considerations for PET brain imaging studies. First the physiological interpretation of the most common outcome measures of binding potential (BPND) and volume of distribution (VT) are described. Next, aspects of acquisition of PET imaging data and blood measurements for analysis are discussed, followed by a summary of standard data analysis techniques. Finally, various applications for the study of mental illness, including group differences, measurements of drug occupancy, and assay of acute neurotransmitter release are discussed.

scholarly journals Harnessing multimodality to enhance quantification and reproducibility of in vivo molecular imaging data

2008 ◽  
Vol 5 (11) ◽  
pp. iii-iv ◽  
Author(s):  
Gilbert D Feke ◽  
W Matthew Leevy ◽  
Sean Orton ◽  
Benjamin Geldhof ◽  
M Catherine Muenker ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Imaging Data
Sign in / Sign up

Export Citation Format

Share Document